Remove 2024 Remove Arrhythmia Remove Atrial Fibrillation
article thumbnail

Novel drug therapies for atrial fibrillation

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 28 February 2024; doi:10.1038/s41569-024-01004-2 Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers.

article thumbnail

Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say

DAIC

Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. However, this reasoning disregards valuable data regarding early arrhythmia recurrences and their potential significance.

article thumbnail

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

DAIC

Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Food and Drug Administration approval of the FARAPULSE PFA System in the first quarter of 2024. The company now anticipates U.S. Caution: Investigational Device. Circulation.

article thumbnail

Atrial fibrillation screening in Syrian patients reporting to the emergency department during the ongoing conflict: a cross-sectional study

Frontiers in Cardiovascular Medicine

BackgroundAtrial fibrillation (AF) is the most common arrhythmia worldwide. Data regarding AF screening in conflict countries emergency departments (ED) is lacking.MethodsWe included consecutive patients >40 years old who reported to the ED of a Syrian tertiary centre between July 2024 and September 2024.

article thumbnail

A multicenter analysis of implantable monitoring device-based diagnosis of supraventricular arrhythmia post patent foramen ovale closure: the OCCL-ILR study

Frontiers in Cardiovascular Medicine

Primary endpoint was the incidence of patients with new onset supraventricular arrhythmia (AF, atrial flutter or any supraventricular tachycardia) lasting >30s, post PFO closure.ResultsA total of 59 patients met the inclusion criteria. A total of 88 supraventricular arrhythmia events (96.6% days (IQR 1321).

article thumbnail

Pulsed field ablation for atrial fibrillation: a comprehensive bibliometric analysis of research trends and emerging Frontiers

Frontiers in Cardiovascular Medicine

BackgroundAtrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, posing significant health burdens. The number of publications increased rapidly from 2019 to 2024, with a notable surge occurring after 2022.

article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

PFA is designed to address AFib, the most common arrhythmia in the US, with a growing patient population. Another Farapulse PFA study looked at the post-ablation atrial arrhythmia (AA) burden associated with PFA and found less AA burden and improved quality of life in the study population.